Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | PDE5A | O76074 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 4/20 | 0.48 |
| ▸ | DRD2 | P14416 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | HTR7 | P34969 | 4/20 | 0.48 |
| ▸ | HTR6 | P50406 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20281071 | 0.86 | HTR1A (0.62) | MEN1KMT2ALMNATP53HTR1A | |
| SCHEMBL20267158 | 0.82 | HTR1A (0.60) | MEN1KMT2ALMNATP53HTR1A | |
| SCHEMBL30526272 | 0.82 | HTR1A (0.60) | MEN1KMT2ALMNATP53HTR1A | |
| SCHEMBL20280952 | 0.82 | CYP1A2 (0.54) | MEN1KMT2ALMNATP53SMN1; SMN2 | |
| SCHEMBL20281070 | 0.81 | APP (0.60) | MEN1KMT2ALMNATP53HTR1A | |
| SCHEMBL20280949 | 0.79 | HTR1A (0.54) | TP53HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL20267012 | 0.78 | HTT (0.57) | MEN1KMT2ALMNATP53NPSR1 | |
| SCHEMBL20280920 | 0.78 | HTR1A (0.54) | MEN1KMT2ATP53HTR1ADRD2 | |
| SCHEMBL20281016 | 0.77 | CYP1A2 (0.67) | MEN1KMT2ALMNATP53SMN1; SMN2 | |
| SCHEMBL20280962 | 0.76 | CYP1A2 (0.67) | MEN1KMT2ALMNATP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718609-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-08-08 | — | — | US | disclosed |
| US-11718609-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-08-08 | — | — | US | disclosed |
| US-20210130338-A1 | Heparanase Inhibitors and Use Thereof | Beta Therapeutics Pty Ltd (AU) | 2021-05-06 | — | — | US | disclosed |
| US-20200093852-A1 | Methods of Treating Ocular Disorders | Beta Therapeutics Pty Ltd (AU) | 2020-03-26 | — | — | US | disclosed |
| WO-2018107226-A1 | METHODS OF TREATING OCULAR DISORDERS | Beta Therapeutics Pty. Ltd. (AU) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018107200-A1 | HEPARANASE INHIBITORS AND USE THEREOF | Beta Therapeutics Pty Ltd (AU) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093852-A1 | Methods of Treating Ocular Disorders | ALDH1A2, HPSE, RB1 | MEN1 3872/4885KMT2A 1503/4885LMNA 2506/4885 |
| US-20210130338-A1 | Heparanase Inhibitors and Use Thereof | HPSE, HEXD, ENGASE | MEN1 3459/4885KMT2A 3540/4885LMNA 2276/4885 |
| US-11718609-B2 | Heparanase inhibitors and use thereof | HPSE, HEXD, ENGASE | MEN1 3459/4885KMT2A 3540/4885LMNA 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.